Atlanta, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of eValuator with a 1,000-bed, Epic-based academic medical center serving central Florida.
eValuator’s pre-bill code audit technology makes it easy for providers to identify, quantify and expedite correction of coding issues with the highest impact on revenue integrity. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and professional-fee encounters through one platform without billing delays.
“We are pleased that our pre-bill revenue integrity solutions continue to gain market traction with large health systems,” stated Ben Stilwill, Chief Executive Officer. “Our team is excited to improve the revenue cycle of these institutions to ensure they are accurately paid for the care they’ve provided.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.59 |
Daily Change: | -0.02 -0.55 |
Daily Volume: | 8,872 |
Market Cap: | US$15.330M |
December 18, 2024 December 16, 2024 October 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load